GSK initiates phase III programme for novel type 2 diabetes medication, Syncria® (albiglutide)
- Details
- Category: GlaxoSmithKline

FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab
- Details
- Category: Amgen

Bristol-Myers Squibb Foundation to Bridge Gaps in Hepatitis C Awareness, Prevention and Care
- Details
- Category: Bristol-Myers Squibb

Immune-boosting effect of Pegasys provides patients with the chance for a clinical cure
- Details
- Category: Roche

New England Journal of Medicine publishes results from the landmark ATHENA trial
- Details
- Category: Sanofi

Sandoz receives European Commission approval for biosimilar filgrastim
- Details
- Category: Novartis

Novartis gains worldwide rights to elinogrel, a Phase II anti-clotting compound
- Details
- Category: Novartis

More Pharma News ...
- Bayer Schering Pharma to invest 100 million Euro in China to build a global R&D center
- HemCon Announces Further Successful Results from Live Nail Infection Anti-Fungal Study
- Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee
- Pfizer to Disclose Payments to US Physicians, Healthcare Professionals and Clinical Investigators
- GlaxoSmithKline and Idenix Pharmaceuticals sign worldwide license agreement for IDX899
- Lundbeck to acquire US-based Ovation Pharmaceuticals, Inc.
- Pfizer and The Pfizer Foundation Recognize "World Cancer Day"